Literature DB >> 30926588

Tear cytokine profiling in patients with superior limbic keratoconjunctivitis who underwent medical treatment or in conjunction with surgical management.

Yi-Chen Sun1,2, Yi-Hua Tang3, Hau-Min Liou3, Wei-Li Chen3, Fung-Rong Hu4,5.   

Abstract

PURPOSE: To determine the correlation between superior limbic keratoconjunctivitis (SLK) and selected tear cytokines and to evaluate the efficacy of these cytokines in monitoring the response of patients with SLK to either medical treatment alone or in combination with conjunctival resection.
DESIGN: A cohort study.
METHODS: Twenty-five eyes of 13 patients with SLK were assigned to either medically responsive or surgical treatment groups depending on their responses 1 month after initial medical treatment. Treatment efficacy was assessed by improvements in clinical grading and decreases in the levels of tear cytokines.
RESULTS: Fourteen eyes were improved by medical treatment alone, whereas satisfactory outcomes were achieved for the remaining 11 eyes after surgical management. The overall grading prior to medical treatment was lower in medically responsive group compared with surgical treatment group (p=0.0139). Among the examined tear cytokines, monocyte chemoattractant protein (MCP)-1 was positively associated with the severity of clinical grading (p=0.0251). While both treatments significantly decreased the levels of MCP-1 and interleukin-6, surgical treatment also decreased the levels of interferon-γ and tumour necrosis factor-α. Notably, overall cytokine levels after surgical treatment were lower than those after medical treatment alone.
CONCLUSIONS: Since an association of tear MCP-1 level with the clinical grading and treatment response of SLK was observed in this study, tear MCP-1 may be a potential indicator of SLK disease severity. According to the degree to which the tear cytokine levels were decreased, surgical treatment appears to be an effective treatment modality for patients with SLK who are refractory to medical treatment alone. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  MCP-1; superior limbic keratoconjunctivitis; tear cytokine

Mesh:

Substances:

Year:  2019        PMID: 30926588     DOI: 10.1136/bjophthalmol-2018-313358

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  3 in total

1.  Recharacterization of superior limbic keratoconjunctivitis via a subdividing grading method in 236 Chinese patients.

Authors:  Chao Cheng; Minyi Zhu; Tianlan Lin; Ziyan Chen; Weiting Zeng; Kunke Li; Ran Xue; Fang Duan; Kaili Wu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-03       Impact factor: 3.117

2.  Tear cytokine profiles in patients with extranodal marginal zone B-cell lymphoma of the ocular adnexa.

Authors:  Wei Xiao; Jingqiao Chen; Huijing Ye; Xiaoyun Chen; Yuxiang Mao; Xian Ji; Shenglan Yang; Huasheng Yang
Journal:  Eye (Lond)       Date:  2021-06-28       Impact factor: 4.456

3.  Metabolomic Alterations in the Tear Fluids of Patients With Superior Limbic Keratoconjunctivitis.

Authors:  Yan Zong; Chao Cheng; Kunke Li; Ran Xue; Ziyan Chen; Xiuping Liu; Kaili Wu
Journal:  Front Med (Lausanne)       Date:  2022-01-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.